FISH (fluorescence in situ hybridisation)
A test that detects changes in the number or arrangement of genetic material in tumour cells.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Detects gene fusions such as ALK, ROS1, or RET.
- Detects amplifications such as HER2 or MET.
Informs decisions
- Suitability of target therapy categories.
- Classification of tumor subtypes.
How the test is done
The labeled probe is attached to a piece of tissue, then read under a special microscope.
- Sample type
- Block tumor tissue
- Estimated result time
- Generally a few business days to one to two weeks.
Limitations
- Requires a network of adequate quality.
- Interpretation of results requires reading experience.
- Reporting thresholds may vary between laboratories.
Related
Cancer types
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Brain Cancer
Subtype
Reason: Memerlukan pemeriksaan
- Lung Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Breast Cancer
Subtype
Reason: Memerlukan pemeriksaan
- Targeted therapy
Treatment category
Reason: Memerlukan pemeriksaan
- ALK
Biomarker
Reason: Diperiksa melalui
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.